Business Description
Nova Leap Health Corp
NAICS : 623312
SIC : 8621
ISIN : CA66980G1090
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.52 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -12.26 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.47 | |||||
Beneish M-Score | -3 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.6 | |||||
3-Year EBITDA Growth Rate | 32.6 | |||||
3-Year EPS without NRI Growth Rate | 9.1 | |||||
3-Year FCF Growth Rate | 7.7 | |||||
3-Year Book Growth Rate | 25.1 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.42 | |||||
9-Day RSI | 45.89 | |||||
14-Day RSI | 45.5 | |||||
6-1 Month Momentum % | 75 | |||||
12-1 Month Momentum % | 40 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.3 | |||||
Quick Ratio | 1.3 | |||||
Cash Ratio | 0.48 | |||||
Days Sales Outstanding | 23.94 | |||||
Days Payable | 26.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | 17.68 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 36.25 | |||||
Operating Margin % | -0.7 | |||||
Net Margin % | -4.07 | |||||
FCF Margin % | 5.15 | |||||
ROE % | -5.75 | |||||
ROA % | -4.61 | |||||
ROIC % | -0.65 | |||||
ROC (Joel Greenblatt) % | -55.68 | |||||
ROCE % | -5.9 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 16.34 | |||||
Price-to-Owner-Earnings | 110 | |||||
PS Ratio | 0.54 | |||||
PB Ratio | 0.75 | |||||
Price-to-Tangible-Book | 5.63 | |||||
Price-to-Free-Cash-Flow | 10.48 | |||||
Price-to-Operating-Cash-Flow | 10 | |||||
EV-to-EBIT | -13.06 | |||||
EV-to-EBITDA | -88.22 | |||||
EV-to-Revenue | 0.58 | |||||
EV-to-Forward-Revenue | 0.51 | |||||
EV-to-FCF | 11.08 | |||||
Price-to-Projected-FCF | 0.49 | |||||
Earnings Yield (Greenblatt) % | -7.65 | |||||
FCF Yield % | 9.49 |